Vitae Pharmaceuticals Reports Third Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Vitae Pharmaceuticals (VTAE) Ends 3Q With Cash Available Through 2016; Piper Jaffray Raises Price Target to $18
November 6, 2015 11:26 AM ESTPiper Jaffray reiterated an Overweight rating on Vitae Pharmaceuticals (NASDAQ: VTAE), and raised the price target to $18.00 (from $16.00), following the company's 3Q earnings report. Vitae ended 3Q:15 with $69 million, sufficient to fund the company through 2016. Lead candidate VTP-43742, inhibiting the RORt/IL-17 pathway, is currently in a multiple ascending dose trial in both healthy... More
Vitae Pharmaceuticals (VTAE) Misses Q3 EPS by 12c
November 6, 2015 8:30 AM ESTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q3 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $175.8 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More